Opinion|Videos|January 15, 2025
Unmet Needs and Future Perspectives of RET-Positive NSCLC
Author(s)Heather A. Wakelee, MD, FASCO, Jacob Sands, MD
Panelists discuss the unmet needs and future perspectives in the treatment of RET-positive non–small cell lung cancer (NSCLC), focusing on areas for improvement in therapy and the potential for new treatment strategies.
Advertisement
Episodes in this series
- Dr. Wakelee: Thank you to Dr Sands for this insightful discussion. Before we end, I would like to get some closing thoughts from Dr Sands on unmet needs and future perspectives on the treatment of RET fusion-positive NSCLC.
Advertisement
Related to this article
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
P. Leia Nghiemphu, MD, discusses INTUITT-NF2 trial findings, the NCCN inclusion of brigatinib, and unmet needs in NF2-related schwannomatosis.
Biagio Ricciuti, MD, PhD, discusses Krascendo 1 data for divarasib, co-mutation–guided sequencing, and emerging RAS inhibitors in KRAS G12C–positive NSCLC.
Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.
Davide Melisi, MD, PhD, discusses INCB161734’s mechanism of action and the DAWN-303 trial design in KRAS G12D-mutated pancreatic cancer.
Breakthroughs with daraxonrasib in pancreatic cancer pave the way for continued investment in understanding the fundamental biology of cancers.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
INCB161734 Combination Data Shape DAWN-303’s All-Comers Design in Frontline KRAS G12D-Mutated PDAC
2
Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC
3
Fox Chase Cancer Center Researchers Identify Potential New Target for Pancreatic Cancer
4
Perioperative Research Success Is Set to Transform Bladder Cancer Care After ESMO 2026
5